The Triple-Agonist Frontier: Understanding Retatrutide and the Risks of Unapproved Weight Loss Drugs
Lina Irawan
The landscape of obesity medicine is currently undergoing a radical transformation. For millions of people, the introduction of GLP-1 receptor agonists—such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro)—has provided…
